Therapeutic stringlengths 8 15 | Format stringclasses 104
values | CH1 Isotype stringclasses 22
values | VD LC stringclasses 11
values | Highest_Clin_Trial (Feb '25) stringclasses 14
values | Est. Status stringclasses 6
values | HeavySequence stringlengths 2 140 | LightSequence stringlengths 2 125 | HeavySequence(ifbispec) stringclasses 124
values | LightSequence(ifbispec) stringclasses 100
values | 100% SI Structure stringlengths 6 224 ⌀ | 99% SI Structure stringclasses 79
values | 95-98% SI Structure stringclasses 80
values | Year Proposed int64 1.99k 2.03k | Year Recommended stringclasses 32
values | Target stringlengths 2 87 | Companies stringlengths 2 1.7k | Conditions Approved stringclasses 137
values | Conditions Active stringlengths 2 910 ⌀ | Conditions Discontinued stringlengths 2 384 ⌀ | Development Tech stringclasses 44
values | Notes stringlengths 3 216 ⌀ | Genetics (Bispecifics delimited with semicolon) stringclasses 32
values | Alternative Therapeutic Names stringlengths 3 215 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abagovomab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS | DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIKKKKKKKKKKKKKKKKKKK | na | na | null | null | null | 2,006 | 2007 | MUC16/CA125 | Menarini | na | na | Ovarian cancer;Pancreatic cancer | null | null | Murine | ACA 125;ACA125;ACA-125 |
Abazistobart | Whole mAb | G4 | Kappa | TBC | TBC | EVKLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKRLEWVATISGGGRYTYYPDTVKGRFTISRDNAKNSHYLQMNSLRAEDTAVYFCASPYGGYFDVWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSISNFLHWYQQKPGQAPRLLIKYASQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSNSWPHTFGQGTKVEIK | na | na | 7vux:HL | null | null | 2,025 | na | PDCD1/CD279/PD1 | Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd | na | Cancer | na | null | null | Chimeric and Humanised | 609A |
Abciximab | Fab | G1 | Kappa | Approved | NFD | EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSA | EIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQTNSWPYTFGGGTKLEIK | na | na | 6v4p:CD | null | null | 1,993 | 1994 | ITGA2B/CD41 | Janssen Biologics BV;Eli Lilly | Coronary artery restenosis;Unstable angina pectoris | na | Arterial occlusive disorders;Myocardial infarction;Stroke | null | Sequence sourced through DrugBank. Biosimilars available from ISU Abxis and Harvest Moon Pharmaceuticals | Chimeric | c7E3;CentoRx;Centrex;ReoPro |
Abelacimab | Whole mAb | G1 | Lambda | Phase-III | Active | QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELSYLYSGYYFDYWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSAWDQRQFDVVFGGGTKLTVL | na | na | 6r8x:CB | null | null | 2,018 | 2019 | F11 | Novartis;Anthos Therapeutics;Labcorp Drug Development;TIMI Study Group | na | Venous Thromboembolism; Stroke;Thrombosis | na | null | Feb '22: Added in missing residues 97 and 98. (Jun '22) Added missing residues at start of VL CDR3. | Genetically human | MAA-868 |
Abiprubart | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQRLEWIGYINPSNDYTKYNQKFKDRATLTADKSANTAYMELSSLRSEDTAVYYCARQGFPYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRRWIYDTSKLASGVPARFSGSGSGTDYTLTISSLEPEDFAVYYCHQLSSDPFTFGGGTKVEIK | na | na | null | null | null | 2,023 | 2024 | TNFRSF5/CD40 | Primatope Therapeutics;Kiniksa Pharmaceuticals | na | Rheumatoid arthritis;Autoimmune disorders | na | null | null | Humanised | KPL404;KPL-404;KPL 404 |
Abituzumab | Whole mAb | G2 | Kappa | Phase-II | Active | QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | ITGAV/CD51 | Merck | na | Colorectal cancer;Systemic scleroderma | Ovarian cancer;Prostate cancer;Solid tumours | null | 4o02 claims to be abituzumab (17E6); but is not | Humanised | DI 17E6;EMD525797 |
Abrezekimab | Fab | G1 | Kappa | Phase-I | Discontinued | QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | IL13 | UCB | na | na | Asthma | null | Jun '22: Added missing FWH3 and CDRL3 residues | Humanised | UCB 4144;UCB4144;UCB-4144;VR-942 |
Abrilumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK | na | na | null | null | null | 2,014 | 2015 | ITGA4B7 | Amgen;AstraZeneca | na | na | Crohn's disease;Ulcerative colitis | null | null | Genetically human | Abrilimumab;AMG-181;MEDI-7183 |
Acapatamab | Bispecific scFv | na;na | Kappa;Lambda | Phase-I/II | Discontinued | QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | FOLH1/GCPII/PSMA;CD3E | Amgen | na | na | Cancers;Prostrate cancer;Metastatic cancer | BiTE Technology. | Genetics of Fv2: musmus/homosap | Genetically human;Chimeric and/or humanised | AMG 160;AMG160;AMG-160 |
Acasunlimab | Bispecific mAb | G1;G1 | Lambda;Kappa | Phase-III | Active | EVQLLEPGGGLVQPGGSLRLSCEASGSTFSTYAMSWVRQAPGKGLEWVSGFSGSGGFTFYADSVRGRFTISRDSSKNTLFLQMSSLRAEDTAVYYCAIPARGYNYGSFQHWGQGTLVTVSS | SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDNDRPSGLPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL | EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS | DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK | None;None | None;None | None;None | 2,020 | 2021 | PDL1/CD274;TNFRSF9/CD137/4-1BB | Genmab;BioNTech | na | Non-small cell lung cancer;Endometrial cancer;Solid tumours | na | null | null | Humanised;Humanised | BNT-311;BNT311;GEN-1046;GEN1046 |
Acimtamig | Bispecific (VH-VK-VH'-VL Homodimer) | na;na | Lambda;Kappa | Phase-II | Active | QVQLVQSGAEVKKPGESLKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGSAYYYDFADYWGQGTLVTVSS | SYVLTQPSSVSVAPGQTATISCGGHNIGSKNVHWYQQRPGQSPVLVIYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQVWDNYSVLFGGGTKLTVL | QVQLQQSGAELARPGASVKMSCKASGYTFTTYTIHWVRQRPGHDLEWIGYINPSSGYSKYNQNFKGKTTLTADKSSNTAYMQLNSLTSEDSAVYYCARRADYGNYEYTWFAYWGQGTTVTVSS | DIVMTQSPKFMSTSVGDRVTVTCKASQNVGTNVAWFQQKPGQSPKVLIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYHTYPLTFGGGTKLEIN | None;None | None;None | 7seg:AB:HL;None | 2,023 | 2023 | FCGR3A/CD16/CD16A;TNFRSF8/CD30 | Affimed Therapeutics | na | Hodgkin's disease;Peripheral T/NK cell lymphoma | na | null | Genetics of both Fvs: musmus/homosap | Chimeric and/or humanised;Chimeric and/or humanised | AFM13;AFM-13 |
Acrixolimab | Whole mAb | G4 | Kappa | Phase-I/II | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFLRYAMHWVRQAPGKGLEWVAVISYDGRYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTTTFDSWGQGTLVTVSS | DIVMTQTPLSLPVTPGEAASISCRSSQSLLDSEDGNTYLDWYLQKPGQSPQLLIYTLSHRASGVPDRFSGSGSGTDFTLEISRVEAEDVGVYYCMQRRDFPFTFGQGTKVDIK | na | na | null | null | null | 2,022 | 2022 | PDCD1/CD279/PD1 | Y-Biologics | na | Solid tumours | na | null | null | Genetically human | YBL-006 |
Actoxumab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | Clostridium difficile Toxin A | Bristol-Myers Squibb;Merck;University of Massachussets Medical School | na | na | Clostridium difficile | Medarex HuMAb Mouse | null | Genetically human | CDA 1;CDA-1;MBL-CDA1;MDX-066;MK-3415A (combination of actoxumab and bezlotoxumab) |
Adakitug | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVESGGGVVQPGRSLRLSCTASGFTFSHYGMYWVRQAPGKGLEWVAVIWYDGSYEYNADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRVGLFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGPSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSLTFGPGTKVDIK | na | na | null | null | null | 2,024 | 2024 | CXCL8 | Bristol-Myers Squibb | na | Colon sarcoma;Myelodysplastic syndromes;Gastric adenocarcinoma | na | null | null | Genetically human | BMS-986253;BMS986253;HuMax-IL8;HuMax-Inflam;MDX018;MDX-018 |
Adalimumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK | na | na | 6cr1:HL/4nyl:AB:CD:EF:HL | 3wd5:HL/8xj0:BA:DC:FE:HG | null | 1,999 | 2000 | TNF/TNFA | Abbvie;MedImmune;180 Life Sciences | Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis;Pyoderma | Dupuytren's contracture;Cognition disorders;Frozen shoulder;Non-alcoholic steatohepatitis | Interstitial cystitis | CAT Phage Display | Many biosimilars and related drugs. | Genetically human | D2E7;HUMIRA |
Adebrelimab | Whole mAb | G4 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS | DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | PDL1/CD274 | Jiangsu Hengrui Medicine;Atridia | Small cell lung cancer | Non-small cell lung cancer;Oesophageal cancer;Cancer;Solid tumours | Haematological malignancies | null | Genetics: musmus/homosap | Chimeric and/or humanised | HTI-1088;HTI1088;HTI-1316;HTI1316;SHR 1316;SHR1316;SHR-1316 |
Adecatumumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDMGWGSGWRPYYYYGMDVWGQGTTVTVSS | ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYDIPYTFGQGTKLEIK | na | na | null | null | null | 2,004 | 2004 | EPCAM/CD326 | Micromet Inc;Merck Sorono;Amgen | na | na | Breast cancer;Colorectal cancer;Prostate cancer | null | Sequence sourced through https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2123299 | Genetically human | MT 201;MT201;MT-201 |
Adezkibart | Whole mAb | G1 | Lambda | TBC | TBC | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYALSWVRQAPGQGLEWMGTRPPTSRTASYAQKFQGRVTITVDESTSTGYMELSSLRSEDTAVYYCASNDFVYGSYRFWGQGTTVTVSS | NFMLTQPHSVSESPGKTVTISCTRTSGNIAGYFVQWYQQRPGSSPTTVIYEDYQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDDYRRAAFGGGTKLTVL | na | na | null | null | null | 2,025 | na | FLT3LG | TBC | TBC | TBC | TBC | TBC | TBC | Genetically human | TBC |
Adimanebart | Whole mAb | G1 | Lambda | TBC | TBC | EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYGMSWVRQAPGKGLEWVSAIPWSGGSTYYKESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRSGRIAFGALDAWGQGTLVTVSS | QTVVTQEPSFSVSPGGTVTLTCGLSSGSVTSSNYPDWYQQTPGQAPRTLIYSTDSRHSGVPDRFSGSILGNKAALTITGAQADDESDYYCGLYSYSGSKNYVFGGGTKLTVL | na | na | null | null | null | 2,025 | na | MUSK | TBC | TBC | TBC | TBC | TBC | TBC | Humanised | TBC |
Adintrevimab | Whole mAb | G1 | Lambda | Phase-II/III | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSSISEDGYSTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFSGHTAWAGTGFEYWGQGTLVTVSS | QSVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRNSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYTFGTGTKVTVL | na | na | null | 7u2d:HL | 7u2e:HL | 2,021 | 2022 | SARS-CoV-2 Spike | Adagio Therapeutics | na | COVID-19 | na | null | null | Genetically human | ADG-20;ADG20 |
Aducanumab | Whole mAb | G1 | Kappa | Approved | NFD | QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK | na | na | 6cnr:HL/6co3:HL | null | null | 2,013 | 2014 | APP | Biogen;Neurimmune | Alzheimer's disease | na | na | null | null | Genetically human | ADUHELM;BIIB 037;BIIB-037;NI-10;NI10 |
Afasevikumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK | na | na | 6ppg:HL:BA | null | null | 2,015 | 2016 | IL17A | NovImmune;Genentech | na | na | Autoimmune disorders;Inflammation | null | null | Genetically human | MCAF-5352A;MCAF5352A;NI-1401;NI1401;RG-7624;RG7624;RO5553110 |
Afimkibart | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYDFTYYGISWVRQAPGQGLEWMGWISTYNGNTHYARMLQGRVTMTTDTSTRTAYMELRSLRSDDTAVYYCARENYYGSGAYRGGMDVWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPWTFGQGTKVEIK | na | na | null | null | null | 2,024 | na | TNFSF15/TL1A/VEGI | Pfizer;Roche | na | Ulcerative colitis;Crohn's disease;Inflammatory bowel diseases | na | null | null | Genetically human | PF 6480605;PF-06480605;PF06480605;RG-6631;RG 6631;RG6631;RO-7790121;RO 7790121;RO7790121;RVT-3101;RVT 3101;RVT3101 |
Alacizumab | di-Fab | na | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRIGEDALDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDIAGSLNWLQQKPGKAIKRLIYATSSLDSGVPKRFSGSRSGSDYTLTISSLQPEDFATYYCLQYGSFPPTFGQGTKVEIK | na | na | null | null | null | 2,007 | 2008 | KDR/CD309/VEGFR2 | UCB | na | na | Non-small cell lung cancer | null | null | Humanised | CDP-791;CDP791 |
Alcestobart | Whole mAb | G4 | Lambda | Phase-II | Active | QVQLQESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWSGGSTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCATGGYWGQGTLVTVSS | DIRLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYSTPYTFGQGTKLTVL | na | na | null | null | null | 2,024 | na | LAG3/CD223 | BeiGene;Leads Biolabs | na | Non-small cell lung cancer;Oesophageal cancer;Squamous cell cancer;Colorectal cancer;Solid tumours | Lymphoma;Malignant melanoma | null | null | Genetically human | LBL-007; LBL007;LBL 007 |
Aldastotug | Whole mAb | G1 | Kappa | Phase-I | Active | EVQLVQSGAEVKKPGESLRISCKGSGYSFTTYWISWVRQMPGKGLEWMGLIDPSDSYTNYSPSFKGHVTISTDKSISTAYLQWSSLKASDTAMYYCARGGYYGSEEDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSRLAWFQQKSGQAPRLLIFDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEFK | na | na | null | null | null | 2,024 | 2024 | SIGLEC15/CD33L3 | Pyxis Oncology | na | Oncology | na | Transgenic Mouse | null | Genetically human | BSI 060T;BSI-060T;BSI060T;PYX 106;PYX-106;PYX106 |
Alemtuzumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK | na | na | 1bey:HL/1ce1:HL | null | null | 2,000 | 2001 | CD52 | Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge | Chronic lymphocytic leukaemia;Multiple sclerosis | Lymphoma;T-cell prolymphocytic leukaemia | Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma | null | null | Humanised | Campath;Campath-1H;LDP-03;LDP03;Lemtrada;Remniq |
Aletekitug | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKVSGEISTGYYFHWVRQAPGKGLEWMGRIDPEDDSTKYAERFKDRVTMTEDTSTDTAYMELSSLRSEDTAVYYCTTWRIYRDSSGRPFYVMDAWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCLASEDIYTYLTWYQQKPGKAPKLLIYGANKLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQGSKFPLTFGQGTKLEIK | na | na | null | null | null | 2,024 | na | IL18 | GSK | na | Atopic dermatitis | Crohn's disease;Delayed graft function;Inflammatory bowel diseases;Type 2 diabetes mellitus | null | null | Humanised | GSK-1070806;GSK 1070806;GSK1070806 |
Alextatug | Whole mAb | G1 | Lambda | Phase-I | Discontinued | EVQLVESGGALVKPGGSLRLSCAASGFTFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL | na | na | null | null | null | 2,023 | 2024 | RNP complex containing PABPC1 | Atreca | na | na | Solid tumours | null | null | Genetically human | ATRC-101;ATRC101;ATRC 101 |
Alirocumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK | na | na | null | null | null | 2,012 | 2013 | PCSK9 | Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital | Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis;Dyslipidaemias | Coronary artery disease | na | VelocImmune Mouse | null | Genetically human | Praluent;REGN-727;REGN727;SAR-236553 |
Alomfilimab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGVVRPGGSLRLSCVASGVTFDDYGMSWVRQAPGKGLEWVSGINWNGGDTDYSDSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDFYGSGSYYHVPFDYWGQGILVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKRGQAPRLLIYGASSRATGIPDRFSGDGSGTDFTLSISRLEPEDFAVYYCHQYDMSPFTFGPGTKVDIK | na | na | 7joo:HL | null | null | 2,020 | 2021 | ICOS/CD278 | Kymab | na | na | Gastic cancers;Non-small cell lung cancer;Melanoma;Hepatocellular carcinoma;Esophageal cancer;Head and neck squamous cell carcinoma | null | null | Genetically human | KY-1044;KY1044;SAR-445256 |
Alnuctamab | Bispecific mAb with Domain Crossover | G1;G1 | Kappa;Lambda | Phase-I/II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK | EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E | Celgene Corporation | na | Multiple myeloma | na | null | Genetics of both Fvs: musmus/homosap | Chimeric and/or humanised;Chimeric and/or humanised | BMS-986349;BMS986349;CC-93269;CC93269;EM-901;EM901 |
Alpitatug | Whole mAb | G1 | Kappa | TBC | Active | QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNWIRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAVYYCATGYYYGSGFWGQGTLVTVSS | DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHWYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIK | na | na | null | null | null | 2,024 | na | KLK2/KLK2A2/hGK-1/hK2 | TBC | TBC | TBC | TBC | TBC | ADC with Satetraxetan (and 225Ac) | Humanised | TBC |
Alsevalimab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | VTCN1/B7H4 | Five Prime Therapeutics | na | na | Solid tumours | null | null | Genetically human | FPA-150;FPA150 |
Amatuximab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS | DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK | na | na | 7ued:HL | 4f33:BA:DC:FE:HG/4f3f:BA/8cxc:HL | null | 2,010 | 2011 | MSLN | Eisai Co Ltd;Morphotek;National Cancer Institute (USA) | na | na | Pancreatic cancer;Solid tumours;Mesothelioma | null | null | Chimeric | MORAb-009; MORAB-009-006;MORAb009 |
Amdokitug | Whole mAb | G1 | Kappa | TBC | TBC | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFDMSWGRQAPGKRLEWVAFMSSGGSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGERYGSYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGKAPKLLISGATSLETGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYWSTPFTFGSGTKLEIK | na | na | null | null | null | 2,025 | na | IL17A | TBC | TBC | TBC | TBC | TBC | TBC | Chimeric and/or humanised | TBC |
Amtabafusp | Whole mAb Fusion | G1 | Lambda | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKSRFTISRDDSKNSLYLEMNSLRTEDTAVYYCVRHGNFGHSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTGHYANWVQQKPGQAPRGLIGGTSNRAPGVPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNRWVFGGGTKLTVL | na | na | null | null | null | 2,024 | na | CD3E | TBC | TBC | TBC | TBC | TBC | TBC | Humanised | TBC |
Amivantamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Approved | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS | AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK | QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK | None;6wvz:HL | None;None | None;None | 2,019 | 2020 | EGFR/ERBB1/HER1;MET/HGFR | Genmab;Janssen Research & Development | Non-small cell lung cancer | Gastic cancer;Oesophageal cancer;Solid tumours | na | null | null | Genetically human;Genetically human | CNTO4424;JNJ 372;JNJ372;JNJ-372;JNJ-61186372;JNJ61176372;JNJ-6372;JNJ6372;RYBREVANT |
Amlenetug | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLLESGGGLVQTGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSAIRSQGDRTDYADSVKGRFTISRDNSQNTLYLQMNSLRAEDTAVYYCAKNWAPFDSWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | 8b9v:HL | null | null | 2,024 | 2024 | SNCA/PARK1/PARK4 | Lundbeck | na | Multiple system atrophy | na | null | null | Genetically human | LU AF82422 |
Amlitelimab | Whole mAb | G4 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGATRYADSVKGRFTISRDNSRNTVYLQMNSLRVEDTAVFYCTKDRLIMATVRGPYYYGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSETDFTLTISSLQPEDFATYYCQQSHSVSFTFGPGTKVDIK | na | na | null | null | null | 2,020 | 2021 | TNFSF4/CD134/CD252/OX40L | Kymab | na | Atopic dermatitis | na | null | null | Genetically human | KY-1005;KY1005;SAR-445229 |
Amostomig | Bispecific mAb | G1;G1 | Lambda;Lambda | Phase-I/Phase-II | Active | QVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMYWVRQAPGKGLEWVSSIEDSSINTGGGTETTYYTDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKGDYYCTTYECQHYYGMDYWGQGTTVTVSS | QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL | EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSDISWSGSNTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARAPLLLAMTFGVGSWGQGTLVTVSS | QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL | None;None | None;None | None;None | 2,024 | 2024 | IAP/CD47/MER6/OA3;PDL1/CD274 | Biocad CJSC | na | Solid tumours | na | null | Fv2 same sequence as Manelimab | Humanised;Humanised | TBC |
Amrecibart | Whole mAb | G4 | Kappa | TBC | TBC | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLDWVSFIRSGGDTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVHPYTWDYGDAFDIWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK | na | na | null | null | null | 2,025 | na | F11 | TBC | TBC | TBC | TBC | TBC | TBC | Genetically human | TBC |
Amubarvimab | Whole mAb | G1 | Kappa | Phase-II/III | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIK | na | na | 7cdi:HL/7xnf:HL/8gx9:HF:IL/7x2k:HL | 7e8m:HL | 7swo:HL | 2,021 | 2022 | SARS-CoV-2 Spike RBD | Brii Biosciences | na | na | COVID-19 | null | null | Genetically human | BRII-196;BRII196 |
Amulirafusp | Whole mAb Fusion | G1 | Kappa | Phase-I/II | Active | QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA | QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKHELK | na | na | null | 4kaq:HL/2osl:AB:HL/4kaq:HL/6y90:HL:CD/6vja:HL:IM/8vgn:AB:HL | null | 2,024 | 2024 | MS4A1/CD20 | ImmuneOnco Biopharmaceuticals | na | Oncology | na | null | null | Chimeric | IMM-0306;IMM 0306;IMM0306 |
Anbenitamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-II/III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA | None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL | 1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 2,020 | 2021 | ERBB2/CD340/HER2 (Domain II);ERBB2/CD340/HER2 (Domain IV) | Alphamab | na | Breast cancer;Gastric cancer | na | null | 4llu is 94.7% identical to ERBB2 (domain II) Fv. ADC with repodatecan reported in PL132 | Humanised;Humanised | KN-026;KN026 |
Andecaliximab | Whole mAb | G4 | Kappa | Phase-III | Discontinued | QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK | na | na | 5th9:HL:IM:JN | null | null | 2,016 | 2017 | MMP9/GELB | Gilead Sciences | na | na | Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma | null | null | Chimeric | GS-5745;GS5745 |
Anetumab | Whole mAb ADC | G1 | Lambda | Phase-II | Discontinued | QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS | DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL | na | na | 8cz8:AA:CC | null | null | 2,013 | 2014 | MSLN | Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA) | na | na | Fallopian tube cancer;Peritoneal cancer;Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma | MorphoSys HuCAL Phage Display | ADC with ravtansine | Genetically human | BAY 94-9343;BAY-94-9343;BAY-94-9343-SPDB-DM4 |
Anifrolumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK | na | na | 4qxg:HL | null | null | 2,013 | 2014 | IFNAR1 | Medarex;Medical University of Vienna;MedImmune | Systemic lupus erythematosus | Lupus nephritis | Rheumatoid arthritis;Scleroderma | Medarex UltiMAb Mouse | null | Genetically human | MDX-1333;MDX1333;MEDI-546;MEDI546;Saphnelo |
Anivovetmab | Canine Whole mAb | G2 | Kappa | Unknown | Active | QVQLKESGPGLVAPSQTLSLTCTVSGFSLSSYHVHWVRQPPGKGLEWLGVMWNDGDTSYNLALNSRLSISRDTSKSQVFFKMSSLQTEDTATYYCARPELPGLTYGVWFPYWGQGTLVTVSA | DIVMTQTPASMSISVGDRVTMNCKASQNVDSNVDWYQQKTGQSPNLLIYKASNRNTGVPDRFTGSGSGTDFTFTISNMQAEDLAVYYCMQSTSYPLTFGSGTKLEIK | na | na | null | null | 3iy6:BA/3jcx:HL | 2,022 | 2022 | Minor Capsid VP2 (Canine) | Kindred Biosciences | na | Canine parvovirus | na | null | Chimeric: Rat/Dog | Chimeric | KIND030;KIND 030;KIND-030 |
Anrukinzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK | na | na | null | null | null | 2,007 | 2008 | IL13 | Pfizer;Wyeth | na | na | Asthma;Ulcerative colitis | null | null | Humanised | IMA-638;IMA638;PF-05230917;PF0523917 |
Anselamimab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLKESGPGLVAPSQSLSITCTVSGFSLSSYGVSWVRQPPGKGLEWLGVIWGDGSTNYHPNLMSRLSISKDISKSQVLFKLNSLQTDDTATYYCVTLDYWGQGTSVTVSS | DVVMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCFQTTYVPNTFGGGTKLEIK | na | na | null | null | null | 2,021 | 2022 | Light Chain Amyloid Fibrils | Caelum Biosciences | na | AA amyloidosis | na | null | Oct '22: Amended target. Targets a conserved epitope across light chain amyloid fibrils: Am J Pathol. 2000;157(4):1239–46;Clin Cancer Res. 2003;9(10):3831S-3838S;Biochemistry. 2007;46(5):1240–7. Chimeric: Mouse/Human | Chimeric | 11-1F4;CAEL-101;CAEL101 |
Ansipastobart | Whole mAb | G1 | Lambda | Phase-I | Active | EVQLLESGGGLVQPGGSLRLSCAASGSSFSSYAYSWVRQAPGKGLEWISAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYSRADEWGRGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSISNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVL | na | na | null | null | null | 2,024 | 2024 | NT5E/CALJA/CD73 | BioRay Pharm | na | Advanced Solid Tumors | na | null | null | Genetically human | BR101;BR-101;BR 101 |
Ansuvimab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS | DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK | na | na | null | 5fha:HL/5fhc:HL | null | 2,020 | 2021 | Zaire Ebolavirus Glycoprotein | Ridgeback Biotherapeutics | Zaire ebolavirus infection | na | na | null | null | Genetically human | EVB114;EVB-114 |
Anumigilimab | Whole mAb | G4 | Kappa | Phase-I | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYWMGWVRQAPGKGLEWVSSISSSGGVTPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLGELGWFDPWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSYLNWYQQKPGKAPKLLIYYASNLQNGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | CSF3R/CD114 | CSL Behring | na | na | Inflammatory diseases;Hidradenitis suppurativa;Localised pustular psoriasis | null | null | Genetically human | CSL-324;CSL324 |
Anvatabart | Whole mAb ADC | G1 | Kappa | Phase-II/III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | na | na | 6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA | 1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL | 5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL | 2,022 | 2023 | ERBB2/CD340/HER2 | Fudan University | na | Solid cancers;Breast cancer | na | null | Anvatabart has an identical V domain to Coprelotamab; Cinrebafusp; Timigutuzumab; and Trastuzumab. ADC with opadotin and pactil | Humanised | ARX788;ARX-788;ARX 788 |
Anzurstobart | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFRGYGISWVRQAPGQGLEWMGWISAYGGETNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREAGSSWYDFDLWGRGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGASFPITFGGGTKVEIK | na | na | 7st5:HL:hl | null | null | 2,022 | 2023 | SIRPA | Celgene Corporation | na | Acute myeloid leukaemia;Myelodysplastic syndromes | Non-Hodgkin's lymphoma;Solid tumours | null | null | Genetically human | BMS-986351;BMS986351;CC-95251;CC95251 |
Apamistamab | Whole mAb Radiolabelled | G1 | Kappa | Phase-III | Active | EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVSS | DIALTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK | na | na | null | null | null | 2,018 | 2019 | PTPRC/CD45 | Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center | na | Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma | Hodgkin's disease;Non-Hodgkin's lymphoma | null | null | Murine | Iomab-ACT;Iomab-B |
Apitegromab | Whole mAb | G4 | Lambda | Preregistration | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVL | na | na | null | null | 6umx:HL:hl | 2,020 | 2021 | pro-MSTN/GDF8/GDF-8/pro-GDF8 | Scholar Rock | na | Spinal muscular atrophy;Muscular atrophy;Spinal cord injuries | na | null | null | Genetically human | SRK-015;SRK015 |
Aplitabart | Whole IgM+J Chain (Cyclic Pentamer) | M3 | Kappa | Phase-I | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK | na | na | null | null | null | 2,024 | 2024 | TNFRSF10B/CD262/DR5/TRAILR2 | IgM Biosciences | na | Colorectal cancer;Non-Hodgkin's lymphoma;Solid tumours | Acute myeloid leukaemia | null | IgM Version of Tigatuzumab (same Fv sequence) | Humanised | IGM-8444;IGM8444 |
Aprutumab | Whole mAb ADC | G1 | Lambda | Phase-I | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL | na | na | null | null | null | 2,016 | 2017 | FGFR2/CD332 | Bayer | na | na | Solid tumours | null | ADC with ixadotin | Genetically human | BAY-1179470;BAY1179470 |
Arcitumomab | Whole mAb | G1 | Kappa | Approved (w) | NFD | EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTTEYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVSS | QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIK | na | na | 1clo:HL | null | null | 1,995 | 1996 | CEA/CEACAM | Immunomedics;Giliad Sciences | Colorectal cancer | na | na | null | null | Murine | null |
Armocibart | Whole mAb | G4 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYGISWVKQAPGQGLEWIGEIYPRSTNTYYNEKFMGKATLTADKSSSTAYMELSSLRSEDTAVYYCARESFYGDYGAMDFWGQGTLVTVSS | DIVLTQSPLSLPVTPGEPASIFCKSSQSLLESDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQGTHFPRTFGQGTKVEIK | na | na | null | null | null | 2,024 | na | TFPI | Suzhou Alphamab Co. Ltd. | TBC | TBC | TBC | TBC | TBC | Chimeric and/or humanised | TBC |
Arumakimig | Bispecific mAb | G1;G1 | Lambda;Kappa | TBC | TBC | EVQLVQSGAEVKKPGSSVKVSCKASGGTFKSYAISWVRQAPGQGLEWMGNIIPMTGQTYYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAAYHPLVFDNWGQGTLVTVSS | DIVLTQPPSVSGAPGQRVTISCSGSSSNIGNHYVNWYQQLPGTAPKLLIYRNNHRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQSWDYSGFSTVFGGGTKLTVL | QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS | EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK | None;None | None;5bvj:HG:FE:DC:BA/4g6j:HL/4g5z:HL/5bvp:HL | None;None | 2,025 | na | IL18;IL1B | TBC | TBC | TBC | TBC | TBC | TBC | Genetically human;Genetically human | TBC |
Ascrinvacumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK | na | na | null | null | null | 2,015 | 2016 | ACVRL1/SKR3 | Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals | na | na | Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer;Age-related macular degeneration;Cancer;Liver Cancer | null | null | Genetically human | PF-03446962;PF03446962 |
Aselizumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVASISTGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARDYDGYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGQGTKVEIK | na | na | null | null | null | 2,003 | 2003 | L-Selectin | PDL Biopharma | na | na | Adult respiratory distress syndrome;Crohn's disease;Psoriasis;Reperfusion injury;Shock | null | null | Humanised | HuDreg-55;HuDreg55 |
Astegolimab | Whole mAb | G2 | Kappa | Phase-III | Active | EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | IL1RL1/ST2 | Amgen;Genentech;University of Leicester | na | Allergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease | Asthma;Rhinosinusitis | null | null | Genetically human | AMG-282;AMG282;RG 6149;RG6149;RG-6149;RO 7187807;RO7187807;RO-7187807 |
Atenastobart | Whole mAb | G1 | Lambda | Phase-I | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSTFTMNWVRQAPGKGLEWVSSISSKGSYIEYAESFKVRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARYGIKNELNWVFDYWGQGTLVTVSS | QSALTQPPSASGSPGQTVTISCTGTSTDVGYYEYVSWYQQHPGKAPKLMIYETSKRLSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYRYEHQVSFGGGTKLTVL | na | na | null | null | null | 2,024 | na | TNFRSF9/CD137/4-1BB | Chugai Pharmaceutical | na | Solid tumours | na | null | null | Genetically human | STA-551;STA 551;STA551 |
Atezolizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK | na | na | 5x8l:FK:HM:GL:JO:SN | 5xxy:HL | null | 2,014 | 2015 | PDL1/CD274 | Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Rese... | Non-small cell lung cancer;Urogenital cancer;Breast cancer;Small cell lung cancer | Bladder cancer;Cervical cancer;Colorectal cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Malignant melanoma;Ovarian cancer;Peritoneal cancer;Prostate cancer;Renal cell carcinoma;Anal cancer;Brain metastases;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Diffuse large B cell lymphoma;Endometrial... | Hodgkin's disease;Myelodysplastic syndromes | Human Phage Display | null | Humanised | MPDL-3280A;MPDL3280A;RG-7446;RG7446;RG7446-42;RO-5541267;RO5541267;TECENTRIQ |
Atibuclimab | Whole mAb | G4 | Kappa | Phase-II | Active | DVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSS | DIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK | na | na | null | null | null | 2,020 | 2021 | CD14 | ICOS Corporation;Implicit Bioscience | na | Acute lung injury;COVID-19 | Adult respiratory distress syndrome;Motor neuron disease;Septic shock | null | null | Chimeric | IC-14;IC14 |
Atidortoxumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLQESGPGLVRPSETLSLTCAVSGYSISSGMGWGWIRQPPGKGLEWIGSIDQRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDAGHAVDMDVWGKGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYVFPLTFGGGTKVEIK | na | na | null | null | null | 2,017 | 2018 | Staphylococcus aureus Toxin A | Adimab;Arsanis;X4 Pharmaceuticals | na | na | Staphylococcal infections | null | null | Genetically human | ASN-1;ASN1;ASN200 (combination of atidortoxumab and berlimatoxumab);ASN-200 |
Atigotatug | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGSVQPGESLRLSCVASGFTFSRYKMNWVRQAPGKGLEWVSYISRSGRDIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAGTVTTYYYDFGMDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK | na | na | null | null | null | 2,024 | 2024 | Fucosyl-GM1 | Bristol Myers Squibb | na | Relapsed/refractory small cell lung cancer | na | null | null | Genetically human | BMS-986012;BMS986012;BMS 986012 |
Atinumab | Whole mAb | G4 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTKLEIK | na | na | null | null | null | 2,010 | 2011 | RTN4/Nogo | Novartis | na | na | Spinal cord injuries | null | null | Genetically human | ATI355;ATI-355 |
Atisnolerbart | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFISYNIFWVRQATGQGLDWMGWMNPFRNNAGYAQKFQGRVTVTWDTSISTAYMELSSLSSEDTAIYYCAREHGSSWGFFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | 7mxl:JK/7n0v:HL | null | null | 2,022 | 2023 | Bet v 1 | Regeneron | na | Allergic rhinitis;Birch pollen allergy | na | null | Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5715. Identical V region sequence to Bremzalerbart. | Genetically human | REGN5713-5714-5715 (combination of Atisnolerbart; Bremzalerbart; and Umesolerbart) |
Atoltivimab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK | na | na | 7tn9:GH:IJ | null | null | 2,018 | 2019 | Zaire Ebolavirus Glycoprotein | Regeneron Pharmaceuticals | na | na | Ebola virus infections | null | null | Genetically human | REGN 3470;REGN3470;REGN-3470;INMAZEB (combination with Maftivimab and Odesivimab) |
Avdoralimab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | C5AR1/CD88 | Novo Nordisk;Innate Pharma | na | na | Rheumatoid arthritis;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours;Bullous pemphigoid | null | null | Genetically human | IPH-5401;IPH5401;NN-8210;NN8210 |
Avelumab | Whole mAb | G1 | Lambda | Approved | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL | na | na | 4nki:HL/5grj:HL | null | null | 2,015 | 2016 | PDL1/CD274 | AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson... | Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma | Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyng... | na | Human Phage Display | Avelumab and Bintrafusp have identical V domains | Genetically human | BAVENCIO;MSB-0010718C;MSB0010718;CPF-06834635;CPF06834635 |
Avitotamig | Whole mAb | G1 | Kappa | TBC | Active | QVQLQQSGAEVVKPGASVKVSCKASGYSFTDYNMYWVRQAPGQGLEWMGYIDPYKGGTIYNQKFQGRATLTRDTSISTAYMELSRLRSDDTAVYYCAREMITAYYFDYWGQGSSVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDINKYIAWYQHKPGKAPKLLIYYASNLQPGVPSRFSGSGSGRDFTFTISSLQPEDIATYYCLQYDNLLTFGAGTKLELK | na | na | null | null | null | 2,024 | 2024 | SIGLEC3/CD33/p67 | Y-mAbs Therapeutics | na | Acute myeloid leukemia | na | TBC | null | Humanised | YMS-5A;YMS5A;YMS 5A |
Avizakimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGTIDPSDQYTIYSQNFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYGFAMDYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGHTLPRTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | IL21 | MedImmune;Boston Pharmaceuticals | na | Systemic lupus erythematosus | Autoimmune disorders | null | null | Humanised | BOS-161721;BOS161721 |
Axatilimab | Whole mAb | G4 | Kappa | Preregistration | Active | EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | CSF1R/CD115/M-CSFR | Syndax Pharmaceuticals;AstraZeneca;UCB | na | Cholangiocarcinoma;Graft-versus-host disease;COVID-19 | Solid tumours | null | null | Humanised | INCA-34176;INCA34176;SNDX-6352;SNDX6352;UCB 6352;UCB6352;UCB-6352 |
Azerutamig | Bispecific Mixed mAb and scFv-CH2-CH3 | G1;G1 | Kappa;Kappa | Phase-II | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGAPMGAAAGWFDPWGQGTVLTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGVSFPRTFGGGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKCLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGCGTKVEIK | None;None | None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA | None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL/5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL | 2,024 | na | KLRK1/NKG2D/CD314;ERBB2/CD340/HER2 | Dragonfly Therapeutics;Gilead Sciences | na | Solid tumours;Breast cancer;Non-small cell lung cancer | na | null | null | Genetically human | DF-1001;DF 1001;DF1001 |
Azintuxizumab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS | DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | SLAMF7/CD319 | AbbVie | na | na | Multiple myeloma | null | ADC with vedotin | Chimeric and humanised | ABBV-838;ABBV838 |
Azirkitug | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLKLSCAASGFIFSNAVMYWVRQASGKGLEWVARIKTKFNNYATYYADAVKGRFTISRDDSKNMVYLQMNSLKTEDTAVYYCTAGDRNKPFAYWGQGTLVTVSS | ETVVTQSPATLSLSPGERATLSCRASTSVITLLHWFQQKPGQAPRLLIHGASNLESRVPARFSGSGSGTDFTLTISSLEPEDFATYFCQQSWNDPYTFGQGTKLEIK | na | na | null | null | null | 2,024 | 2024 | CCR8/CKR-L1/CDw198 | AbbVie | na | na | Non-small cell lung cancer;Squamous cell cancer | TBC | null | Humanised | ABBV 514;ABBV-514;ABBV514 |
Bafisontamab | Bispecific Mixed mAb and Fab | G1;na | Kappa;Kappa | Phase-I/II | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISASNGNTYYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVYADYADYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGINTWLAWYQQKPGKAPKLLIYAASSLKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK | 5sx4:HL:JI/5sx5:HL:JK;None | None;None | None;None | 2,021 | 2022 | EGFR/ERBB1/HER1;MET/HGFR | EpimAb Biotherapeutics | na | Non-small cell lung cancer;Solid tumours | na | null | Fv1 is Panitumumab | Genetically human;Humanised | EMB-01;EMB01 |
Balertatug | Whole mAb | G1 | Kappa | TBC | TBC | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK | na | na | null | null | null | 2,025 | na | CD70 | TBC | TBC | TBC | TBC | TBC | TBC | Chimeric and/or humanised | TBC |
Balonkibart | Whole mAb | G4 | Kappa | TBC | TBC | EVQLVESGGGLVQPGGSLRLSCAASGFSFVSYVMGWVRQAPGKGLEWVSSISGSLTNTYYADPVKGRFTISRDNSKNTLYLQMNSLRAEDTAAYYCVTYDILTGHLFDYWGQGTLVTVSS | AIQMTQSPSSLSASVGDRVTITCRSSQGIRNDFGWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTINNLQPEDFATYYCLQDYTYPFTFGPGTKVDIK | na | na | null | null | null | 2,025 | na | NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA | TBC | TBC | TBC | TBC | TBC | TBC | Genetically human | TBC |
Balstilimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | PDCD1/CD279/PD1 | Agenus;Ludwig Institute for Cancer Research | na | Cervial cancer;Solid tumours;Colorectal cancer;Haemangiosarcoma;Soft tissue sarcoma | na | null | null | Genetically human | AGEN-2034;AGEN2034;RebmAb-700;RebmAb700 |
Bamlanivimab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK | na | na | 7l3n:DE/7kmg:AB:DE | null | null | 2,020 | 2021 | SARS-CoV-2 Spike | Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases | COVID-19 | na | na | null | null | Genetically human | LY 3819253;LY3819253;LY-3819253;LY CoV 555;LY-CoV-555 |
Bapineuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS | DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK | na | na | null | null | 4ojf:HL/4hix:HL | 2,005 | 2006 | APP | JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation | na | na | Alzheimer's disease | null | Jain paper: "Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL" | Humanised | AAB-001;AAB001 |
Bapotulimab | Whole mAb | G2 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRLPYGDFWDSWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIR | na | na | null | null | null | 2,020 | 2021 | ILDR2 | Bayer | na | Solid tumours;Squamous cell cancer | na | null | null | Genetically human | BAY-1905254;BAY1905254 |
Barecetamab | Whole mAb | G1 | Lambda | Phase-I | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL | na | na | 7d85:BC:EF | null | null | 2,020 | 2021 | ERBB3/HER3 | ISU Abxis | na | na | Solid tumours;Head and neck cancer | Antibody Phage Display | null | Genetically human | ISU-104; ISU104 |
Barzolvolimab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYINWVRQAPGKGLEWIARIYPGSGNTYYNEKFKGRATLTADKSTSTAYMQLSSLRSEDTAVYFCARGVYYFDYWGQGTTVTVSS | DIVMTQSPSSLSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISSLQPEDFADYFCQQYNSYPRTFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | KIT/CD117 | Celldex Therapeutics | na | Chronic idiopathic urticaria | na | null | Genetics: musmus/homosap | Chimeric and/or humanised | CDX-0159;CDX0159 |
Basiliximab | Whole mAb | G1 | Kappa | Approved | NFD | QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS | QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK | na | na | 1mim:HL/3iu3:AB:CD:HL | null | null | 1,996 | 1997 | IL2RA/CD25 | Cerimon Pharmaceuticals;Novartis | Renal transplant rejection;Transplant rejection | na | Ulcerative colitis;Uveitis | null | null | Chimeric | CHI 621;CHI621;CHI-621;Simulect |
Batoclimab | Whole mAb | G1 | Lambda | Preregistration | Active | QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSS | SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | FCGRT/FcRn | Immunovant Sciences | na | Graves' Ophtalmopathy;Myasthenia gravis;Autoimmune disorders;Neuromyelitis optica;Idiopathic thrombocytopenic purpura | na | null | null | Genetically human | HBM-9161;HBM9161;HL-161;HL161;HL-61;HL61;IMVT 1401;IMVT-1401;IMVT1401;RVT 1401;RVT-1401;RVT1401 |
Bavituximab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS | DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK | na | na | null | null | null | 2,006 | 2007 | Phosphatidylserine | Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center | na | Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours | Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer | null | null | Chimeric | 3G4;Tarvacin |
Bavunalimab | Bispecific Mixed mAb and scFv | G1;na | Kappa;Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFDDAWMSWVRQAPGKGLEWVAEISTKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTAVYYCTRLATWDWYFDVWGQGTTVTVSS | DIVLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKPPKLLIYAASELESGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPFTFGSGTKLEIK | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNYKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHLGPFDLWGQGTMVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | None;None | None;None | None;None | 2,020 | 2021 | LAG3/CD223;CTLA4/CD152 | Xencor | na | na | Solid tumours | null | Bavunalimab is the new name for Pavunalimab (PL125). (Jun '22) Corrected IMGT H25 S->A. Genetics of both Fvs: musmus/homosap | Chimeric and/or humanised;Chimeric and/or humanised | XmAb-22841;XmAb22841;XmAb-841;XmAb841 |
Bebtelovimab | Whole mAb | G1 | Lambda | Approved | Active | QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVL | na | na | 7mmo:AB:DE | null | null | 2,022 | 2022 | SARS-CoV-2 Spike RBD | Eli Lilly;AbCellera | COVID-19 | na | na | null | null | Genetically human | LY-3853113;LY3853113;LY-CoV1404;LY CoV1404 |
Becotatug | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQESGPGLVKPSETLSLTCTVSGFSLSNYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDYYDYEFAYWGQGTLVTVSS | EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK | na | na | null | null | null | 2,022 | 2023 | EGFR/ERBB1/HER1 | CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology | na | Cancers;Non-small cell lung cancer;Metastatic cancers | na | null | ADC with vedotin | Humanised | JMT101;JMT-101 |
Bedinvetmab | Canine Whole mAb | G2 | Lambda | Approved | Active | EVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS | QSVLTQPTSVSGSLGQRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL | na | na | null | null | null | 2,018 | 2019 | NGFB (Canine) | na | na | Canine lupus familiaris | na | null | June '22: Corrected FWL1 sequence | Genetically canine | ZTS-00508841;ZTS00508841;LIBRELA |
Befovacimab | Whole mAb | G2 | Lambda | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMDWVRQAPGKGLEWVSSIRGSRGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLYRYWFDYWGQGTLVTVSS | SYELTQPPSVSVSPGQTARITCSGDNLPKYYAHWYQQKPGQAPVVVIFYDVNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWWSSTPVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | TFPI | na | na | Haemophilia | na | null | null | Genetically human | BAY-109;BAY109;BAY-1093884;BAY1093884 |
Begelomab | Whole mAb | G2b | Kappa | Phase-II/III | Active | QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS | QIVLTQSPAIMSASPGEKVTITCSASSSVSYMNWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPNTFGGGTKLEIK | na | na | null | null | null | 2,014 | 2015 | DPP4/ADCP2/CD26 | ADIENNE | na | Graft-versus-host disease | na | null | null | Murine | SAND-26;SAND26 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 4